Search results
Added:
5 months ago
Added:
2 months ago
Navigate the diagnostic complexities of cardiac amyloidosis through expert multimodality imaging techniques with Dr Vasvi Singh.This comprehensive presentation, part of the Cardiomyopathies track, addresses the critical role of advanced imaging in diagnosing cardiac amyloidosis. Dr Singh explores the nuanced differences between SPECT and SPECT-CT imaging capabilities, providing practical insights…
View more
Added:
2 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly…
View more
Added:
3 months ago
Added:
6 months ago
Added:
2 months ago
ESC Congress 2025 - Digitoxin reduced the risk of all-cause mortality and hospitalisation in patients with worsening heart failure.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Udo Bavendiek to explore the DIGIT-HF trial, investigating whether digitoxin can improve outcomes in patients with advanced chronic heart failure and reduced ejection fraction.This landmark study…
View more
Added:
5 months ago
In this short video, Dr Ovidiu Chioncel shares why acute heart failure remains a critical area of focus in cardiology, highlighting the urgent need for improved strategies in diagnosis and management.This conversation sets the stage for his upcoming Special Focus in Cardiac Failure Review (Impact Factor: 4.2) in 2026, which will explore this topic further.
View more
Added:
1 year ago
TCT Conference 2024 - Clinical outcomes between percutaneous mitral valve repair (PMVR) and mitral valve surgery in patients with atrial mitral regurgitation (MR).Dr Stephan Baldus (University of Köln Medical Center, DE) joins us onsite at TCT Conference to discuss the findings from MATTERHORN (NCT02371512; University of Köln).MATTERHORN is a multicenter, randomized controlled clinical trial,…
View more
Added:
1 month ago
Added:
3 months ago
Source:
Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal disease characterised by the deposition of amyloid fibrils in the heart. A new analysis from the HELIOS-B trial has found that key echocardiographic measures are strong predictors of clinical outcomes and that the RNA interference (RNAi) therapeutic vutrisiran attenuates the decline in cardiac function in this patient…
View more